Recent studies on retatruded, a dual activator for glucagon-like peptide-1 and gastric inhibitory polypeptide, indicate encouraging findings in addressing weight gain and type 2 diabetes. Early data from clinical experiments point to substantial diminutions in body mass and improved glucose control. Ongoing research is centered on long-term safety